| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000014544 |
| Receipt No. | R000016917 |
| Official scientific title of the study | Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 |
| Date of disclosure of the study information | 2014/07/14 |
| Last modified on | 2019/01/15 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 | |
| Title of the study (Brief title) | Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2 | |
| Region |
|
|
| Condition | ||
| Condition | Non-small-cell lung cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate feasibility and efficacy of Carboplatin plus Nab-Paclitaxel in chemotherapy-naive patients with advanced non-small-cell lung cancer and a performance status of 2 |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | Phase I: Dose limiting toxicity
Phase II: Progression free survival |
| Key secondary outcomes | Phase I: Adverse event, Response rate
Phase II: Adverse event, Response rate, Overall survival |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Carboplatin plus Nab-Paclitaxel | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Pathologically confirmation of non-small-cell lung cancer
2) Stage IIIB/IV and chemo-naive non-small-cell lung cancer 3) ECOG PS 2 4) Evaluable lesions 5) Aged 20 or more 6) Adequate organ functions 7) Expected survival over 90 days 8) Written informed consent |
|||
| Key exclusion criteria | 1) Symptomatic brain metastasis
2) Interstitial pneumonia with usual interstitial pneumonia pattern on chest CT 3) Grade 2 or more peripheral sense neuropathy 4) With uncontrolled pleural effusion, ascites or pericardial effusion 5) Treated with palliative radiotherapy within the past two weeks 6) Active concomitant malignancy 7) Severe complication 8) HBs antigen positive 9) Previous severe drug allergy 10) Continuous systemic administration of steroid |
|||
| Target sample size | 33 | |||
| Research contact person | |
| Name of lead principal investigator | Toshiaki Takahashi |
| Organization | Shizuoka cancer center |
| Division name | Division of Thoracic Oncology |
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan |
| TEL | (+81)055-989-5222 |
| t.takahashi@scchr.jp | |
| Public contact | |
| Name of contact person | Kazuhisa Nakashima |
| Organization | Shizuoka cancer center |
| Division name | Division of Thoracic Oncology |
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan |
| TEL | (+81)055-989-5222 |
| Homepage URL | |
| ka.nakashima@scchr.jp | |
| Sponsor | |
| Institute | Shizuoka cancer center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 静岡県立静岡がんセンター(静岡県)
和歌山県立医科大学病院(和歌山県) 倉敷中央病院(岡山県) 広島市立広島市民病院(広島県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016917 |